Literature DB >> 21458739

Airway microbiology and host defences in paediatric non-CF bronchiectasis.

Keith Grimwood1.   

Abstract

Bronchiectasis in children without cystic fibrosis is most common in socioeconomically disadvantaged communities. Recurrent pneumonia in early childhood and defective pulmonary defences are important risk factors. These help establish a 'vicious cycle' of impaired mucociliary clearance, infection, airway inflammation and progressive lung injury. Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis and Pseudomonas aeruginosa are the main infecting pathogens. H. influenzae predominates across all ages, while P. aeruginosa is found in older children with advanced disease. It is uncertain whether viruses and upper airway commensal bacteria play an important aetiological role. Overall, the microbiological data are limited however and there are difficulties obtaining reliable respiratory specimens from young children. Bronchiectasis is a complex disorder resulting from susceptibility to pulmonary infection and poorly regulated respiratory innate and adaptive immunity. Airway inflammatory responses are excessive and persist, even once infection is cleared. Improved specimen collection, molecular techniques and biomarkers are needed to enhance management.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21458739     DOI: 10.1016/j.prrv.2010.10.009

Source DB:  PubMed          Journal:  Paediatr Respir Rev        ISSN: 1526-0542            Impact factor:   2.726


  13 in total

1.  A simple, semiselective medium for anaerobic isolation of anginosus group streptococci from patients with chronic lung disease.

Authors:  Richard D Waite; David W Wareham; Samuel Gardiner; Robert A Whiley
Journal:  J Clin Microbiol       Date:  2012-01-11       Impact factor: 5.948

2.  Kinetics of IgM and IgA antibody response to 23-valent pneumococcal polysaccharide vaccination in healthy subjects.

Authors:  Katharina Schütz; Richard G Hughes; Antony Parker; Isabella Quinti; Vojtech Thon; Monica Cavaliere; Martina Würfel; Wilhelm Herzog; J Engelbert Gessner; Ulrich Baumann
Journal:  J Clin Immunol       Date:  2012-09-25       Impact factor: 8.317

3.  Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi-centre randomized controlled trial.

Authors:  Patricia C Valery; Peter S Morris; Keith Grimwood; Paul J Torzillo; Catherine A Byrnes; I Brent Masters; Paul A Bauert; Gabrielle B McCallum; Charmaine Mobberly; Anne B Chang
Journal:  BMC Pediatr       Date:  2012-08-14       Impact factor: 2.125

Review 4.  Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults.

Authors:  Khin Hnin; Chau Nguyen; Kristin V Carson; David J Evans; Michael Greenstone; Brian J Smith
Journal:  Cochrane Database Syst Rev       Date:  2015-08-13

5.  Does a 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine prevent respiratory exacerbations in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: protocol for a randomised controlled trial.

Authors:  Kerry-Ann F O'Grady; Keith Grimwood; Allan Cripps; Edward K Mulholland; Peter Morris; Paul J Torzillo; Nicholas Wood; Heidi Smith-Vaughan; Amber Revell; Andrew Wilson; Peter Van Asperen; Peter Richmond; Ruth Thornton; Sheree Rablin; Anne B Chang
Journal:  Trials       Date:  2013-09-05       Impact factor: 2.279

6.  The Saudi Thoracic Society guidelines for diagnosis and management of noncystic fibrosis bronchiectasis.

Authors:  Hamdan Al-Jahdali; Abdullah Alshimemeri; Abdullah Mobeireek; Amr S Albanna; Nehad N Al Shirawi; Siraj Wali; Khaled Alkattan; Abdulrahman A Alrajhi; Khalid Mobaireek; Hassan S Alorainy; Mohamed S Al-Hajjaj; Anne B Chang; Stefano Aliberti
Journal:  Ann Thorac Med       Date:  2017 Jul-Sep       Impact factor: 2.219

7.  In utero exposure to arsenic alters lung development and genes related to immune and mucociliary function in mice.

Authors:  Kathryn A Ramsey; Anthony Bosco; Katherine L McKenna; Kim W Carter; John G Elliot; Luke J Berry; Peter D Sly; Alexander N Larcombe; Graeme R Zosky
Journal:  Environ Health Perspect       Date:  2012-12-04       Impact factor: 9.031

8.  Bronchiectasis exacerbation study on azithromycin and amoxycillin-clavulanate for respiratory exacerbations in children (BEST-2): study protocol for a randomized controlled trial.

Authors:  Anne B Chang; Keith Grimwood; Andrew C Wilson; Peter P van Asperen; Catherine A Byrnes; Kerry-Ann F O'Grady; Theo P Sloots; Colin F Robertson; Paul J Torzillo; Gabrielle B McCallum; Ian B Masters; Helen M Buntain; Ian M Mackay; Jacobus Ungerer; Joanne Tuppin; Peter S Morris
Journal:  Trials       Date:  2013-02-20       Impact factor: 2.279

9.  Airway inflammatory markers in individuals with cystic fibrosis and non-cystic fibrosis bronchiectasis.

Authors:  David A Bergin; Killian Hurley; Adwait Mehta; Stephen Cox; Dorothy Ryan; Shane J O'Neill; Emer P Reeves; Noel G McElvaney
Journal:  J Inflamm Res       Date:  2013-01-23

10.  Polymicrobial airway bacterial communities in adult bronchiectasis patients.

Authors:  Paul Purcell; Hannah Jary; Audrey Perry; John D Perry; Christopher J Stewart; Andrew Nelson; Clare Lanyon; Darren L Smith; Stephen P Cummings; Anthony De Soyza
Journal:  BMC Microbiol       Date:  2014-05-20       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.